Ad26.COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2
Neutralizing antibodies detected in 90 percent or more of all participants on day 29 after the first vaccine dose.
Neutralizing antibodies detected in 90 percent or more of all participants on day 29 after the first vaccine dose.
Passengers without proof of a negative test will not be allowed to board flights to America
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
Brilacidin is a first-in-class host defense protein mimetic.
The open-label, controlled study enrolled adults hospitalized with COVID-19 and severe pneumonia, acute lung injury or acute respiratory distress syndrome.
47 percent experience fatigue, with no correlation between any measures of persistent disease and initial disease severity
The study was conducted by Pfizer and the University of Texas Medical Branch.
Early administration of high-titer convalescent plasma against SARS-CoV-2 reduces progression in mildly ill older adults
In base case of modeling study, 59 percent of transmission attributed to presymptomatic and asymptomatic individuals
The FDA is alerting clinical laboratory staff and health care providers regarding the risk of false negative results with any SARS-CoV-2 test if a mutation occurs in the part of the virus’ genome assessed by that test.